Switzerland-based Vaderis Therapeutics, a clinical-stage biopharmaceutical company focused on developing targeted therapies for rare vascular diseases, has closed a private US$152m Series B financing and initiation of HEROIC, the company’s global Phase 3 clinical study evaluating engasertib (VAD044) in patients with hereditary hemorrhagic telangiectasia (HHT).
The Series B financing, co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, and existing investors Medicxi and Droia, are expected to fund the company’s planned operations through regulatory submissions and potential US regulatory approval.
Following the closing, Vaderis’ board comprises Giovanni Mariggi of Medicxi, Colin Walsh of Goldman Sachs Alternatives, Giuliano Marostica of TCGX, Francesco Draetta of Omega Funds, Nick Williams of Medicxi, Azmi Nabulsi, president and CEO of Vaderis, and Rahul Ballal, who serves as an independent director.
“[The financing] represents a defining moment for HHT patients,” said Nabulsi. “This milestone reflects the dedication of our patients, investigators, study teams, and advocacy organisations.”
